enGene Therapeutics Statistics
NASDAQ: ENGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.75-0.055 (-3.06%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
enGene Therapeutics by the numbers
enGene Therapeutics has a market capitalization of $116.9 million based on 67.02M shares outstanding. With trailing EPS of $-2.07, enGene Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 5.5% below its 50-day average and 65.2% below its 200-day average.
Average daily trading volume is 759.27K shares, or about $1.3 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
ENGN valuation vs. peer median
| Metric | ENGN | Peer median | Difference |
|---|---|---|---|
| Market cap | $116.94M | $125.40M | -7% |
| Avg. volume | 759.27K | 900.10K | -16% |
Peer median across 8 companies: TNYA, LENZ, BDTX, HUMA, ATRA, ARMP, AVXL, OTLK.
Valuation
- Market cap
- $116.94M
- EPS (TTM)
- $-2.07
- Shares outstanding
- 67.02M
Price and trading
- Previous close
- 1.80
- Open
- 1.80
- Day range
- 1.74 – 1.86
- 52-week range
- 1.40 – 12.25
- 52-week change
- -75.11%
- Beta
- —
- Volume
- 708.29K
- Average volume
- 759.27K
Dividends and events
- Annual dividend
- None
- Next earnings date
- Sep 8, 2026
Additional statistics
- Market Cap
- 116.94M
- Forward Pe
- -1.20
- Eps
- -2.07
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 12.25
- Week52 Low
- 1.40
- Avg Volume
- 759.27K
- Shares Outstanding
- 67.02M
- Ma50
- 1.85
- Ma200
- 5.01
- Earnings Date
- Sep 8, 2026
- Pct From52w High
- -85.76%
- Pct From52w Low
- 24.64%